chartexchange

Zentalis reports survival data from azenosertib ovarian cancer study

Clinical Trials Arena | Oct 19, 2026 5:41 AM EDT

Zentalis Pharmaceuticals has reported interim overall survival results from the DENALI Part 1b study evaluating azenosertib in patients with platinum-resistant ovarian cancer.
The post Zentalis reports survival data from azenosertib ovarian cancer study appeared first on Clinical Trials Arena .

Read original article